{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peripheral+blood+for+correlative+studies&page=6",
    "query": {
      "intervention": "Peripheral blood for correlative studies",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 617,
    "total_pages": 62,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peripheral+blood+for+correlative+studies&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peripheral+blood+for+correlative+studies&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T12:18:12.575Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01868503",
      "title": "Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Male Breast Cancer",
        "Recurrent Breast Cancer",
        "Stage IIIA Breast Cancer",
        "Stage IIIB Breast Cancer",
        "Stage IIIC Breast Cancer"
      ],
      "interventions": [
        {
          "name": "lapatinib ditosylate",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2013-07",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2017-06-26",
      "last_synced_at": "2026-10-14T12:18:12.575Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01868503"
    },
    {
      "nct_id": "NCT02960646",
      "title": "Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Acute Myeloid Leukemia",
        "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome",
        "Aplastic Anemia",
        "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Chronic Myelomonocytic Leukemia",
        "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Lymphoblastic Lymphoma",
        "Myelodysplastic Syndrome",
        "Myeloproliferative Neoplasm",
        "Plasma Cell Myeloma",
        "Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
        "Recurrent Hodgkin Lymphoma",
        "Recurrent Non-Hodgkin Lymphoma",
        "Recurrent Plasma Cell Myeloma",
        "Therapy-Related Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Peripheral Blood Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 11,
      "start_date": "2017-01-18",
      "completion_date": "2023-02-13",
      "has_results": false,
      "last_update_posted_date": "2023-02-16",
      "last_synced_at": "2026-10-14T12:18:12.575Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02960646"
    },
    {
      "nct_id": "NCT00336024",
      "title": "Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anaplastic Medulloblastoma",
        "Medulloblastoma",
        "Supratentorial Embryonal Tumor, Not Otherwise Specified",
        "Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor"
      ],
      "interventions": [
        {
          "name": "Autologous Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Leucovorin Calcium",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "2 Years",
        "sex": "ALL",
        "summary": "Up to 2 Years"
      },
      "enrollment_count": 91,
      "start_date": "2007-10-22",
      "completion_date": "2025-09-30",
      "has_results": true,
      "last_update_posted_date": "2026-01-23",
      "last_synced_at": "2026-10-14T12:18:12.575Z",
      "location_count": 129,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 100 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00336024"
    },
    {
      "nct_id": "NCT02631746",
      "title": "Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Adult T-Cell Leukemia/Lymphoma",
        "Adult T-Cell Leukemia/Lymphoma",
        "Chronic Adult T-Cell Leukemia/Lymphoma",
        "HTLV-1 Infection",
        "Lymphomatous Adult T-Cell Leukemia/Lymphoma",
        "Smoldering Adult T-Cell Leukemia/Lymphoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pharmacogenomic Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2017-02-23",
      "completion_date": "2019-07-31",
      "has_results": true,
      "last_update_posted_date": "2025-03-14",
      "last_synced_at": "2026-10-14T12:18:12.575Z",
      "location_count": 6,
      "location_summary": "Baltimore, Maryland • Bethesda, Maryland • The Bronx, New York + 1 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02631746"
    },
    {
      "nct_id": "NCT00005803",
      "title": "Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prolymphocytic Leukemia",
        "Recurrent Adult Hodgkin Lymphoma",
        "Recurrent Childhood Hodgkin Lymphoma",
        "Recurrent Childhood Non-Hodgkin Lymphoma",
        "Recurrent Chronic Lymphocytic Leukemia",
        "Recurrent Non-Hodgkin Lymphoma",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Childhood Hodgkin Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Hodgkin Lymphoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Refractory Small Lymphocytic Lymphoma",
        "T-Cell Chronic Lymphocytic Leukemia",
        "T-Cell Prolymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Autologous Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Carmustine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Peripheral Blood Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Therapeutic Autologous Lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER",
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "Up to 75 Years"
      },
      "enrollment_count": 76,
      "start_date": "1999-09",
      "completion_date": "2018-10",
      "has_results": true,
      "last_update_posted_date": "2020-01-29",
      "last_synced_at": "2026-10-14T12:18:12.575Z",
      "location_count": 4,
      "location_summary": "Salt Lake City, Utah • Seattle, Washington",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005803"
    },
    {
      "nct_id": "NCT02519322",
      "title": "Neoadjuvant and Adjuvant Checkpoint Blockade",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cutaneous Melanoma",
        "Mucosal Melanoma",
        "Ocular Melanoma",
        "Stage III Acral Lentiginous Melanoma AJCC v7",
        "Stage IIIB Cutaneous Melanoma AJCC v7",
        "Stage IIIB Uveal Melanoma AJCC v7",
        "Stage IIIC Cutaneous Melanoma AJCC v7",
        "Stage IIIC Uveal Melanoma AJCC v7",
        "Stage IV Acral Lentiginous Melanoma AJCC v6 and v7",
        "Stage IV Cutaneous Melanoma AJCC v6 and v7",
        "Stage IV Uveal Melanoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Relatlimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2016-02-02",
      "completion_date": "2023-01-26",
      "has_results": true,
      "last_update_posted_date": "2024-04-05",
      "last_synced_at": "2026-10-14T12:18:12.575Z",
      "location_count": 2,
      "location_summary": "New York, New York • Houston, Texas",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02519322"
    },
    {
      "nct_id": "NCT01575522",
      "title": "Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Estrogen Receptor Negative",
        "HER2/Neu Negative",
        "Progesterone Receptor Negative",
        "Recurrent Breast Carcinoma",
        "Stage IV Breast Cancer",
        "Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Tivantinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2012-03",
      "completion_date": "2013-07",
      "has_results": true,
      "last_update_posted_date": "2016-03-21",
      "last_synced_at": "2026-10-14T12:18:12.575Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01575522"
    },
    {
      "nct_id": "NCT00954473",
      "title": "Study of Blood Samples From Patients With Osteosarcoma",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Localized Osteosarcoma",
        "Metastatic Osteosarcoma",
        "Recurrent Osteosarcoma"
      ],
      "interventions": [
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1000,
      "start_date": "2009-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-05-19",
      "last_synced_at": "2026-10-14T12:18:12.575Z",
      "location_count": 1,
      "location_summary": "Arcadia, California",
      "locations": [
        {
          "city": "Arcadia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00954473"
    },
    {
      "nct_id": "NCT01262222",
      "title": "Patients Undergoing Major Cancer Surgery: Incidence and Predictive Value for Postoperative Cardiac Events",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "High Risk for Postoperative Cardiovascular Events"
      ],
      "interventions": [
        {
          "name": "endothelial function testing",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 67,
      "start_date": "2010-12",
      "completion_date": "2018-07-11",
      "has_results": false,
      "last_update_posted_date": "2018-07-13",
      "last_synced_at": "2026-10-14T12:18:12.575Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01262222"
    },
    {
      "nct_id": "NCT00323323",
      "title": "CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma"
      ],
      "interventions": [
        {
          "name": "CHOP",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Plasma Samples",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2004-03",
      "completion_date": "2016-10",
      "has_results": false,
      "last_update_posted_date": "2017-01-20",
      "last_synced_at": "2026-10-14T12:18:12.575Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00323323"
    }
  ]
}